Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients
Abstract
:1. Introduction
2. Cachexia Treatment and Implications for Survival: Pre-Clinical and Clinical Studies
3. Cachexia Treatment and Implications for Cancer Treatment Toxicity
4. Cachexia Treatment and Potential Implications for Outcomes on Immunotherapy
5. Endpoints for Cachexia Trials
6. Patient Selection in Lung Cancer Trials
7. Summary
Funding
Conflicts of Interest
References
- Baracos, V.E.; Martin, L.; Korc, M.; Guttridge, D.C.; Fearon, K.C.H. Cancer-associated cachexia. Nat. Rev. Dis. Primers 2018, 4, 17105. [Google Scholar] [CrossRef] [PubMed]
- The National Lung-Cancer Screening Trial Research Team. Reduced mortality with low-dose computed tomography screening. N. Engl. J. Med. 2011, 365, 395–409. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Sahar, L.; Portier, K.M.; Ward, E.M.; Jemal, A. Cancer death rates in US congressional districts. CA Cancer J. Clin. 2015, 65, 339–344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirsch, F.R.; Scagliotti, G.V.; Mulshine, J.L.; Kwon, R.; Curran, W.J.J.; Wu, Y.L.; Paz-Ares, L. Lung cancer: Current therapies and new targeted treatments. Lancet 2017, 389, 299–311. [Google Scholar] [CrossRef]
- Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [Google Scholar] [CrossRef]
- Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Perez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer [KEYNOTE-010]: A randomised controlled trial. Lancet 2016, 387, 1540–1550. [Google Scholar] [CrossRef]
- Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fulop, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef]
- Gandhi, L.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [Google Scholar] [CrossRef]
- Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Mazieres, J.; Hermes, B.; Cay Senler, F.; Csoszi, T.; Fulop, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2040–2051. [Google Scholar] [CrossRef]
- Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N. Engl. J. Med. 2018, 378, 2288–2301. [Google Scholar] [CrossRef]
- Horn, L.; Mansfield, A.S.; Szczesna, A.; Havel, L.; Krzakowski, M.; Hochmair, M.J.; Huemer, F.; Losonczy, G.; Johnson, M.L.; Nishio, M.; et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2220–2229. [Google Scholar] [CrossRef] [PubMed]
- Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N. Engl. J. Med. 2018, 379, 2342–2350. [Google Scholar] [CrossRef] [PubMed]
- Vinod, S.K.; O’Connell, D.L.; Simonella, L.; Delaney, G.P.; Boyer, M.; Peters, M.; Miller, D.; Supramaniam, R.; McCawley, L.; Armstrong, B. Gaps in optimal care for lung cancer. J. Thorac. Oncol. 2008, 3, 871–879. [Google Scholar] [CrossRef] [PubMed]
- Schwarz, S.; Prokopchuk, O.; Esefeld, K.; Groschel, S.; Bachmann, J.; Lorenzen, S.; Friess, H.; Halle, M.; Martignoni, M.E. The clinical picture of cachexia: A mosaic of different parameters [experience of 503 patients]. BMC Cancer 2017, 17, 130. [Google Scholar] [CrossRef]
- Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011, 12, 489–495. [Google Scholar] [CrossRef]
- Sealy, M.J.; Dechaphunkul, T.; van der Schans, C.P.; Krijnen, W.P.; Roodenburg, J.L.N.; Walker, J.; Jager-Wittenaar, H.; Baracos, V.E. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin. Nutr. 2019. [Google Scholar] [CrossRef]
- Sjoblom, B.; Benth, J.S.; Gronberg, B.H.; Baracos, V.E.; Sawyer, M.B.; Flotten, O.; Hjermstad, M.J.; Aass, N.; Jordhoy, M. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clin. Lung Cancer 2017, 18, e129–e136. [Google Scholar] [CrossRef]
- Dercle, L.; Ammari, S.; Champiat, S.; Massard, C.; Ferte, C.; Taihi, L.; Seban, R.D.; Aspeslagh, S.; Mahjoubi, L.; Kamsu-Kom, N.; et al. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. Eur. J. Cancer 2016, 65, 33–42. [Google Scholar] [CrossRef]
- Turner, D.C.; Kondic, A.G.; Anderson, K.M.; Robinson, A.G.; Garon, E.B.; Riess, J.W.; Jain, L.; Mayawala, K.; Kang, J.; Ebbinghaus, S.W.; et al. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin. Cancer Res. 2018, 24, 5841–5849. [Google Scholar] [CrossRef]
- Temel, J.S.; Abernethy, A.P.; Currow, D.C.; Friend, J.; Duus, E.M.; Yan, Y.; Fearon, K.C. Anamorelin in patients with non-small-cell lung cancer and cachexia [ROMANA 1 and ROMANA 2]: Results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016, 17, 519–531. [Google Scholar] [CrossRef]
- Crawford, J.; Prado, C.M.; Johnston, M.A.; Gralla, R.J.; Taylor, R.P.; Hancock, M.L.; Dalton, J.T. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients [POWER Trials]. Curr. Oncol. Rep. 2016, 18, 37. [Google Scholar] [CrossRef] [PubMed]
- Solheim, T.S.; Laird, B.J.A.; Balstad, T.R.; Bye, A.; Stene, G.; Baracos, V.; Strasser, F.; Griffiths, G.; Maddocks, M.; Fallon, M.; et al. Cancer cachexia: Rationale for the MENAC [Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia] trial. BMJ Support. Palliat. Care 2018, 8, 258–265. [Google Scholar] [CrossRef] [PubMed]
- Lerner, L.; Tao, J.; Liu, Q.; Nicoletti, R.; Feng, B.; Krieger, B.; Mazsa, E.; Siddiquee, Z.; Wang, R.; Huang, L.; et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 2016, 7, 467–482. [Google Scholar] [CrossRef] [PubMed]
- Murphy, K.T.; Hossain, M.I.; Swiderski, K.; Chee, A.; Naim, T.; Trieu, J.; Haynes, V.; Read, S.J.; Stapleton, D.I.; Judge, S.M.; et al. Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer. Cancer Res. 2019, 79, 706–719. [Google Scholar] [CrossRef] [PubMed]
- Baracos, V.E. Bridging the gap: Are animal models consistent with clinical cancer cachexia? Nat. Rev. Clin. Oncol. 2018, 15, 197–198. [Google Scholar] [CrossRef] [PubMed]
- Tseng, Y.C.; Kulp, S.K.; Lai, I.L.; Hsu, E.C.; He, W.A.; Frankhouser, D.E.; Yan, P.S.; Mo, X.; Bloomston, M.; Lesinski, G.B.; et al. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. J. Natl. Cancer Inst. 2015, 107, djv274. [Google Scholar] [CrossRef] [Green Version]
- Zhou, X.; Wang, J.L.; Lu, J.; Song, Y.; Kwak, K.S.; Jiao, Q.; Rosenfeld, R.; Chen, Q.; Boone, T.; Simonet, W.S.; et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142, 531–543. [Google Scholar] [CrossRef]
- Naito, T. Evaluation of the true endpoint of cancer clinical trials for cancer cachexia. Asia-Pac. J. Oncol. Nurs. 2019, 6, 227–233. [Google Scholar] [CrossRef]
- Jatoi, A.; Steen, P.D.; Atherton, P.J.; Moore, D.F.; Rowland, K.M.; Le-Lindqwister, N.A.; Adonzio, C.S.; Jaslowski, A.J.; Sloan, J.; Loprinzi, C. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome [N02C4]: An Alliance trial. Ann. Oncol. 2017, 28, 1957–1963. [Google Scholar] [CrossRef]
- Golan, T.; Geva, R.; Richards, D.; Madhusudan, S.; Lin, B.K.; Wang, H.T.; Walgren, R.A.; Stemmer, S.M. LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia Sarcopenia Muscle 2018, 9, 871–879. [Google Scholar] [CrossRef]
- Prado, C.M.; Baracos, V.E.; McCargar, L.J.; Reiman, T.; Mourtzakis, M.; Tonkin, K.; Mackey, J.R.; Koski, S.; Pituskin, E.; Sawyer, M.B. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 2009, 15, 2920–2926. [Google Scholar] [CrossRef] [PubMed]
- Gielda, B.T.; Marsh, J.C.; Zusag, T.W.; Faber, L.P.; Liptay, M.; Basu, S.; Warren, W.H.; Fidler, M.J.; Batus, M.; Abrams, R.A.; et al. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: A single-institution experience of 144 patients. J. Thorac. Oncol. 2011, 6, 1079–1086. [Google Scholar] [CrossRef] [PubMed]
- Baatar, D.; Patel, K.; Taub, D.D. The effects of ghrelin on inflammation and the immune system. Mol. Cell. Endocrinol. 2013, 340, 44–58. [Google Scholar] [CrossRef]
- Crawford, J. What are the criteria for response to cachexia treatment. Ann. Palliat. Med. 2019, 8, 43–49. [Google Scholar] [CrossRef] [PubMed]
- Patel, J.; Pereira, J.R.; Chen, J.; Liu, J.; Guba, S.C.; John, W.J.; Orlando, M.; Bonomi, P.D. Relationshio between efficacy outcomes and weight gain during treatment of advanced non-squamous, non-small cell lung cancer patients. Ann. Oncol. 2016, 27, 1612–1619. [Google Scholar] [CrossRef] [PubMed]
- Laird, B.; Fallon, M. Treating cachexia: An evolving landscape. Ann. Oncol. 2017, 28, 2055–2056. [Google Scholar] [CrossRef] [PubMed]
- McDermott, M.M.; Spring, B.; Berger, D.S.; Treat-Jacobson, D.; Conte, M.S.; Creager, M.A.; Criqui, M.H.; Ferrucci, L.; Gornik, H.L.; Guralnik, J.M.; et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease The HONOR Randomized Clinical Trial. JAMA 2018, 319, 1665–1676. [Google Scholar] [CrossRef] [PubMed]
- LeBlanc, T.W.; Samsa, G.W.; Wolf, S.P.; Locke, S.C.; Cella, D.F.; Abernethy, A.P. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy [FAACT] scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome [CACS]. Support. Care Cancer 2015, 23, 2341–2347. [Google Scholar] [CrossRef]
- Kluetz, P.G.; Slagle, A.; Papadopoulos, E.J.; Johnson, L.L.; Donoghue, M.; Kwitkowski, V.E.; Chen, H.; Sridhara, R.; Farrell, A.T.; Keegan, P.; et al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic AdverseEvents, Physical Function, and Disease-Related Symptoms. Clin. Cancer Res. 2016, 22, 1553–1558. [Google Scholar] [CrossRef]
- Martin, L.; Senesse, P.; Gioulbasanis, I.; Antoun, S.; Bozzetti, F.; Deans, C.; Strasser, F.; Thoresen, L.; Jagoe, R.; Chasen, M.; et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 2015, 33, 90–99. [Google Scholar] [CrossRef]
- Proctor, M.J.; Morrison, D.S.; Talwar, D.; Balmer, S.M.; Fletcher, C.D.; O’Reilly, D.S.; Foulis, A.K.; Horgan, P.C.; McMillan, D.C. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur. J. Cancer. 2011, 47, 2633–2641. [Google Scholar] [CrossRef] [PubMed]
- Proctor, M.J.; McMillan, D.C.; Morrison, D.S.; Fletcher, C.D.; Horgan, P.G.; Clarke, S.J. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br. J. Cancer 2012, 107, 695–699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Derman, B.A.; Macklis, J.A.; Azeem, M.S.; Sayidine, S.; Basu, S.; Esmail, F.; Borgia, J.A.; Bonomi, P.; Fidler, M.J. Realtionships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer 2017, 17, 141–147. [Google Scholar] [CrossRef] [PubMed]
Study Identifier | Randomized | Cancer Type | Accrual Target | Status | Intervention |
---|---|---|---|---|---|
NCT 03740351 | Yes | Non-small cell lung cancer | 316 | Recruiting | Anamorelin Hydorchloride |
NCT 03743064 | Yes | Non-small cell lung cancer | 316 | Recruiting | Anamorelin Hydrochloride |
Eudra CT 2012-002282-19 | Yes | Lung/pancreatic cancers | 240 | Recruiting | Nutrition, exercise, ibuprofen |
NCT 03283488 | Yes | Multiple cancers | 52 | Not yet recruiting | Megestrol/Mirtazepine |
NCT 01614990 | Yes | Multiple cancers | 8 | Recruiting | Macimorelin |
NCT 03207724 | No | Pancreatic cancer | 16 | Recruiting | Xilonix/Onivyde/5FU |
NCT 03631459 | No | Lung/GI cancers | 100,000 | Not yet recruiting | Kanglaite |
NCT 04065815 | No | Multiple cancers | 100 | Recruiting | Exercise, protein Supplement |
NCT 03720158 | Yes | Head and Neck cancer | 86 | Recruiting | Omega-3 fatty acids |
NCT 02330926 | No | Gynecological cancers | 150 | Recruiting | Nutritional supplements Ibuprofen |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bonomi, P.; Fidler, M.J.; Shah, P.; Borgia, J. Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers 2019, 11, 1619. https://doi.org/10.3390/cancers11111619
Bonomi P, Fidler MJ, Shah P, Borgia J. Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers. 2019; 11(11):1619. https://doi.org/10.3390/cancers11111619
Chicago/Turabian StyleBonomi, Philip, Mary Jo Fidler, Palmi Shah, and Jeffrey Borgia. 2019. "Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients" Cancers 11, no. 11: 1619. https://doi.org/10.3390/cancers11111619